Various studies have found a link between fibromyalgia and ADHD, with some urging clinicians to evaluate the presence of attention deficit hyperactivity disorder (ADHD) in individuals who have a history of fibromyalgia. ADHD is a condition characterized by persistent impulsivity, hyperactivity, impaired concentration and inattention, as well as disorganized behavior, anxiety and emotional instability. The CDC estimates that while more than 8% of children have been diagnosed with this condition thus far, less than 1% of adults have received the same consideration.
Fibromyalgia is a chronic pain disorder linked to modified activity of the neurotransmitters involved in pain sensitivity, with deficits in concentration, attention and memory. Figures from the CDC show that this chronic disorder affects approximately 4 million individuals in America, which makes up about 2% of the country’s adult population.
The lead author of a previous study that focused on this link, Sebastián Moyano, stated that his group had noticed a high prevalence of adult and childhood ADHD among fibromyalgia patients. Moyano noted that most of these patients hadn’t been diagnosed with ADHD as children. His preliminary study was conducted in 2018 and included 37 patients with fibromyalgia, with more than 70% testing positive for ADHD.
Moyano recently concluded a follow-up study, which involved 71 controls and 60 patients with fibromyalgia. This recent study confirmed his prior findings, with Moyano noting that the researchers also discovered that cognitive impairment was higher in fibromyalgia patients in comparison to the control group. For this study, the researchers assessed memory, language, attention and various aspects of executive function. In the report, Moyano noted that clinicians should ask their fibromyalgia patients about any cognitive symptoms they had experienced and refer their patients to psychiatrists or neurologists if there were any complaints.
He added that he’d also like to see rheumatologists focus more on the ailment’s aspects and work together with psychiatrists and neurologists in their care teams.
Other studies that have produced similar results to Moyano’s study include a 2021 study that screened individuals with fibromyalgia for the presence of ADHD. The researchers found that more than 24% of these fibromyalgia patients had ADHD, which was linked to higher functional impairment and greater symptom severity for fibromyalgia.
A separate study carried out in 2018 by van Rensberg in South Africa also found that chronic neurodevelopmental disorders that impaired an individual’s cognition were linked to dopamine’s function, noting that ADHD could be linked with pain disorders via shared mechanisms.
As more information becomes available about the link between fibromyalgia and other health conditions, the urgency felt by established companies such as Silo Pharma Inc. (OTCQB: SILO) to develop new treatments for fibromyalgia climbs up a notch higher.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
